0
No hay productos en el carro de la compra
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Casa > Solutions for VZV vaccine and drug development

VZV vaccines and drugs R&D solutions

VZV vaccines and drugs R&D solutions
BACKGROUND
VZV vaccines and drugs R&D solutions
Herpes zoster (HZ), commonly referred to as shingles, is caused by the reactivation of latent varicella-zoster virus (which causes both varicella and herpes zoster). HZ frequently presents as a painful debilitating rash, including skin inflammation and blisters, and sometimes causes scarring and permanent pigment changes. The cumulative incidence of HZ was recently estimated between 2.9 and 19.5 cases per 1000 population worldwide.
Previous studies have shown the VZV glycoprotein E (gE) to be the most abundant viral glycoprotein on the virion envelope and the infected cell surface. Conserved glycoprotein E (gE) is essential for viral replication and transmission between ganglion cells, thus making it an ideal target subunit vaccine antigen. It is also one of the most important VZV protective antigens capable of inducing cellular and humoral immunity during natural varicella infection as well as following vOka vaccination, where gE has been successfully used in the herpes zoster vaccine ShingrixTM .

Current updates as to where we stand with eliminating varicella zoster virus (VZV):

The first VZV vaccine, Zostavax, was developed by Merck and was approved for marketing in 2006.

Shingrix is a VZV subunit vaccine developed by GSK and was approved by the US FDA in October 2017. The improved efficacy and marketing of Shingrix, the Zostavax market share was quickly diminished and has been discontinued.

SKYZoster™ is a live vaccine was approved in South KMFDS in September 2017 based on results of clinical trials conducted in domestic and global institutions.

In 2023, the live attenuated herpes zoster vaccine developed by Changchun Baker Biotechnology Co., Ltd. obtained the biological products batch certificate from the National Medical Products Administration.

VZV vaccines and drugs R&D development solutions
The development and improvement of vaccines remain the current prevention and control of the principal means of varicella zoster virus infection. Explore ViruStop's total solution for VZV vaccine development!
Product type Molecule Cat. No. Product Description
Main Features

Over 90% purity verified by SDS-PAGE;

The binding activity of the antigen and its antibody was verified by ELISA with a linear range of 0.1-4ng/mL;

The proteins are expressed in HEK293 cells, which makes sure the proteins'structure is closer to the natural conformation.

High precision: CV values of intra- and inter-assay precision are <10%;

High recovery rate: the recovery rate is within 80%-120%;

Provide kits for human and mouse sample detection, supporting the evaluation of humoral immunity in preclinical and early clinical stages.

High sensitivity: The sensitivity of the kit is over 39 pg/mL;

Wide detection range: The detection range of the kit is 39-1250pg/mL, which can meet the detection needs of different concentrations;

High precision: CV values of intra- and inter-assay precision are <10%.

High sensitivity and specificity, can accurately detect gE protein in samples;

Recombinant expression in HEK293 cells with good batch-to-batch stability;

Can be used for gE protein detection or as an antibody standard.

Assay Data

gE Recombinant Protein

SDS-PAGE
gE Recombinant Protein

Varicella zoster virus (strain Oka vaccine) Envelope Glycoprotein E (gE), His Tag on SDS-PAGE under non-reducing (NR) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.

Bioactivity-ELISA
gE Recombinant Protein

Immobilized Varicella zoster virus (strain Oka vaccine) Envelope Glycoprotein E (gE), His Tag (Cat. No. GLE-V52H3) at 1 μg/mL (100 μL/well) can bind Anti-Glycoprotein E (VZV) Antibody, Human IgG1 (4G2) with a linear range of 0.02-1 ng/mL (QC tested).

Bioactivity-SPR
gE Recombinant Protein

Anti-Glycoprotein E (VZV) Antibody, Human IgG1 (4G2) (Cat. No. VZV-M545) captured on Protein A Chip can bind Varicella zoster virus (strain Oka vaccine) Envelope Glycoprotein E (gE), His Tag (Cat. No. GLE-V52H3) with an affinity constant of 4.81 nM as determined in SPR assay (Biacore 8K) (Routinely tested).

gE Antigen Detection Kit

Sensitivity
gE Antigen Detection Kit

The detection range of Cat. No. RAS-A102 is 39-1250pg/mL, and the sensitivity is 39pg/mL.

Accuracy
gE Antigen Detection Kit

The recovery of Cat. No. RAS-A102 is within 80%-120%

Precision
gE Antigen Detection Kit

The intra-assay and inter-assay precision of Cat. No. RAS-A102 were both<10%.

IgG Antibody Titer Detection Kits

Accuracy
IgG Antibody Titer Detection Kits

The recovery of Cat. No. RAS-T103 is within 80%-120%.

Precision
IgG Antibody Titer Detection Kits

The intra-assay and inter-assay precision of Cat. No. RAS-T103 were both<10%.

VZV vaccines and drugs R&D solutions

ACRO Quality

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Email
Correo electrónico
Fax
Fax
+1 888-377-6111
Address
Address
Lichtstrasse 35,4056 Basel, Switzerland

Dejar un mensaje